World Medical Innovation Forum
May 19-21, 2021
FUJIFILM Diosynth Biotechnologies is delighted to be attending World Medical Innovation Forum hosted by Mass General Brigham, May 19-21, 2021.
Join Us on Wednesday – May 19, 2021 at 4:00 pm
Thomas Page PhD, VP, Engineering and Asset Development, FUJIFILM Diosynth Biotechnologies, College Station, Texas will be participating in a panel discussion followed by a Q&A
David Hallal, CEO, ElevateBio will be moderating the panel.
Additional speakers include:
Dannielle Appelhans, SVP TechOps and Chief Technical Officer, Novartis Gene Therapies
Rahul Singhvi, ScD, CEO and Co-Founder, National Resilience, Inc.
During this panel they will be discussing:
GCT Manufacturing | Vector Production | Autologous and Allogeneic | Stem Cells | Supply Chain | Scalability & Management
The modes of GCT manufacturing have the potential of fundamentally reordering long-established roles and pathways. While complexity goes up the distance from discovery to deployment shrinks. With the likelihood of a total market for cell therapies to be over $48 billion by 2027, groups of products are emerging. Stem cell therapies are projected to be $28 billion by 2027 and non-stem cell therapies such as CAR-T are projected be $20 billion by 2027. The manufacturing challenges for these two large buckets are very different. Within the CAR-T realm there are diverging trends of autologous and allogeneic therapies and the demands on manufacturing infrastructure are very different.
Questions for the panelists are:
- Help us all understand the different manufacturing challenges for cell therapies. What are the trade-offs among storage cost, batch size, line changes in terms of production cost and what is the current state of scaling naïve and stem cell therapy treatment vs engineered cell therapies?
- For cell and gene therapy what is the cost of Quality Assurance/Quality Control vs. production and how do you think this will trend over time based on your perspective on learning curves today?
- Will point of care production become a reality? How will that change product development strategy for pharma and venture investors? What would be the regulatory implications for such products?
- How close are allogeneic CAR-T cell therapies? If successful what are the market implications of allogenic CAR-T? What are the cost implications and rewards for developing allogeneic cell therapy treatments?
For the agenda and registration please visit World Medical Innovation Forum